


# Product data sheet



MedKoo Cat#: 201310 Name: Etalocib CAS#: 161172-51-6 Chemical Formula: C <sub>33</sub> H <sub>32</sub> FN <sub>2</sub> O <sub>6</sub> Exact Mass: 285.30316 Molecular Weight: 566.59	
Product supplied as:	Powder
Purity (by HPLC):	≥ 98%
Shipping conditions	Ambient temperature
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years. In solvent: -80°C 3 months; -20°C 2 weeks.

## 1. Product description:

Etalocib, also known as LY293111 and VML295, is a novel diaryl ether carboxylic acid derivative, is a potent and selective inhibitor of the lipoygenase pathway either directly through 5'-lipoygenase or via antagonism of the leukotriene B<sub>4</sub> (LTB<sub>4</sub>) receptor. LY293111 has antineoplastic activity in a variety of preclinical models.

## 2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

## 3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	98.5	173.85

## 4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.76 mL	8.82 mL	17.65 mL
5 mM	0.35 mL	1.76 mL	3.53 mL
10 mM	0.18 mL	0.88 mL	1.76 mL
50 mM	0.04 mL	0.18 mL	0.35 mL

## 5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of "Calculator"

## 6. Recommended literature which reported protocols for in vitro and in vivo study

### In vitro study

1. Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE. Leukotriene B<sub>4</sub> receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells. *Anticancer Drugs*. 2007 Jun;18(5):535-41. doi: 10.1097/01.cad.0000231477.22901.8a. PMID: 17414622.
2. Jackson WT, Froelich LL, Boyd RJ, Schrementi JP, Saussy DL Jr, Schultz RM, Sawyer JS, Sofia MJ, Herron DK, Goodson T Jr, Snyder DW, Pechous PA, Spaethe SM, Roman CR, Fleisch JH. Pharmacologic actions of the second-generation leukotriene B<sub>4</sub> receptor antagonist LY293111: in vitro studies. *J Pharmacol Exp Ther*. 1999 Jan;288(1):286-94. PMID: 9862783.

### In vivo study

1. Tong WG, Ding XZ, Hennig R, Witt RC, Standop J, Pour PM, Adrian TE. Leukotriene B<sub>4</sub> receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. *Clin Cancer Res*. 2002 Oct;8(10):3232-42. PMID: 12374694.

## 7. Bioactivity

### Biological target:

Estropipate is a form of estrogen, used to treat symptoms of menopause, also used to prevent osteoporosis.

### In vitro activity

# Product data sheet



In conclusion, LY293111 induces apoptosis in human pancreatic cancer cells through the mitochondria-mediated pathway. LY293111 also induces S-phase arrest with downregulation of CDK2, cyclin A and cyclin E.

Reference: Anticancer Drugs. 2007 Jun;18(5):535-41. <https://pubmed.ncbi.nlm.nih.gov/17414622/>

## In vivo activity

In studies using AsPC-1 and HPAC cell xenografts in athymic mice, LY293111 treatment markedly inhibited tumor growth over a 24-day treatment period, as measured by both tumor volume and tumor weight.

Reference: Clin Cancer Res. 2002 Oct;8(10):3232-42. <https://pubmed.ncbi.nlm.nih.gov/12374694/>

*Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.*